

Inhalation Devices and Propellants:

Key Recommendations¹

- The inhalation device that best fits the needs of the individual patient should be chosen.
- Inhaled drug delivery is recommended over oral or parenteral delivery for adrenergic bronchodilators and glucocorticosteroids.
- With adequate teaching, adults and older children can use any of the commercially available hand-held inhalation devices. MDIs with spacers can be considered for all age groups, and specifically MDIs with valved spacer and face mask are advocated for young children and the elderly. Dry-powder inhalers can provide adequate drug delivery for most children by the time they reach age 5 years. (Note: ADVAIR[®] DISKUS[®] is indicated in children as young as 4 years of age.² Consult respective prescribing information for other products.)
- Patients' method of using their inhalation device must be reassessed and reinforced periodically.
- Health care professionals must teach correct inhaler technique when devices are prescribed and dispensed.

References: 1. Boulet LP, Becker A, Aboult D, et al. Canadian asthma consensus report, 1999. *CMAJ* 1999;161(11 Suppl):S44-S50. 2. Product Monograph of "ADVAIR", GlaxoSmithKline Inc., October 2000.

Respiratory Inhaler Quick Reference Guide

^aADVAIR[®] (salmeterol xinafoate/fluticasone propionate) Inhalation preparation is indicated for the maintenance treatment of asthma in patients with reversible obstructive airways disease where the use of a combination product is considered to be appropriate. ADVAIR[®] should not be used in patients whose asthma can be managed by occasional use of short-acting, inhaled β_2 -agonists. ADVAIR[®] contains a long-acting β_2 -agonist and should not be used as a rescue medication. To relieve acute asthmatic symptoms, a short-acting bronchodilator (e.g., salbutamol) should be used.

ADVAIR[®] DISKUS[®] Inhalation preparation contains lactose (which contains milk protein) and is contraindicated in patients with IgE mediated allergic reactions to lactose or milk.

In adolescents and adults, the most common side effects are throat irritation (2%), hoarseness/dysphonia (2%), headache (2%), and candidiasis (2%) which can be reduced by rinsing and gargling with water after inhalation; and palpitations (1%). In children aged 4 to 11, the only adverse event with an incidence of >2% was candidiasis.

HPA-axis function and hematological status should be assessed periodically. Height should also be regularly monitored in children and adolescents receiving prolonged treatment with inhaled corticosteroids. Concomitant use of fluticasone propionate and ritonavir, an HIV protease inhibitor, has been shown to result in clinically significant systemic side effects and should be avoided unless the potential benefit to the patient outweighs the risk.

Interim results from a large U.S. study (Salmeterol Multicentre Asthma Research Trial - SMART) showed increased risks of asthma-related deaths and other serious respiratory-related outcomes in patients receiving salmeterol, (a component of ADVAIR[®]/ADVAIR[®] DISKUS[®]) vs. those on placebo, in addition to their usual asthma therapy. The study was prematurely terminated after enrollment of half the intended number of patients. Post-hoc analyses of the data suggest that the risks may be greater in African-American patients and in those patients who did not report using inhaled corticosteroids (ICS) at study entry. Since the study did not assess the ICS dosages actually used by the patients, and may be different from those in ADVAIR[®] products, it is not known whether the increased risks seen with salmeterol would also apply to ADVAIR[®]/ADVAIR[®] DISKUS[®]. The ADVAIR[®]/ADVAIR[®] DISKUS[®] dosage form prescribed should reflect the patient's optimal inhaled steroid requirement.

ADVAIR[®] is available in 2 dosage forms, ADVAIR[®] DISKUS[®] for patients 4 years and older and ADVAIR[®] MDI for patients 12 years and older.



Consult respective prescribing information before prescribing.

^aADVAIR[®], FLOVENT[®], SEREVENT[®], VENTOLIN[®] and DISKUS[®] are registered trademarks used under license by GlaxoSmithKline Inc. With the appearance, shape, and size of the DISKUS[®] Inhalation device is used under license by GlaxoSmithKline Inc. BRICANTIL[®], OXZELE[®], PULMICORT[®], SYMBICORT[®] and TURBUHALER[®] are trademarks of the AstraZeneca Group. ATROVENT[®], SPRIKEL[®] and Handihaler[®] are registered trademarks of Boehringer Ingelheim (Canada) Ltd. Licensed use. ARONIR[®] and QVAR[®] are trademarks of JMI Pharmaceuticals, licensed use. ALVESCO[®] is a registered trademark of ALVAXA Pharma AG, licensed use. The colours on this reference guide may vary slightly from the actual product due to the limitations of the printing process.

gsk GlaxoSmithKline

88981

BIWAG 38
48



CONTROLLERS

Anti-Inflammatories



FLOVENT® DISKUS® Inhalation Device (Fluticasone propionate)
Available in 50, 100, 250 & 500 mcg per inhalation
GlaxoSmithKline



FLOVENT® HFA (Fluticasone propionate)
Available in 50, 125 & 250 mcg per inhalation
GlaxoSmithKline



PULMICORT® TURBUHALER® (Budesonide)
Available in 100, 200 & 400 mcg per inhalation
AstraZeneca



ALVESCO® (Ciclesonide)
Available in 100 & 200 mcg per inhalation
ALTANA Pharma AG



QVAR® (Beclomethasone dipropionate)
Available in 50 & 100 mcg per inhalation
3M Pharmaceuticals

Combination Medications



ADVAIR® DISKUS® Inhalation Device (Salmeterol xinafoate/fluticasone propionate)
Available in 50/100, 50/250 & 50/500 mcg per inhalation
GlaxoSmithKline



ADVAIR® MDI (Salmeterol xinafoate/fluticasone propionate)
Available in 25/125 & 25/250 mcg per inhalation
GlaxoSmithKline



SYMBREONORT® TURBUHALER® (Budesonide/formoterol fumarate dihydrate)
Available in 100/6 & 200/6 mcg per inhalation
AstraZeneca



VENTOLIN® DISKUS®
Inhalation Device
(Salbutamol sulfate)
200 mcg per inhalation
GlaxoSmithKline



BRICANYL® TURBUHALER®
(Terbutaline sulfate)
0.5 mg per inhalation
AstraZeneca

Long-Acting Bronchodilators



SEREVENT® DISKUS® Inhalation Device (Salmeterol xinafoate)
50 mcg per inhalation
GlaxoSmithKline



SPIRIVA® HandiHaler® Inhalation Device (Tiotropium bromide monohydrate)
18 mcg per inhalation
Boehringer Ingelheim



OXZE® TURBUHALER® (Formoterol fumarate dihydrate)
Available in 6 & 12 mcg per inhalation
AstraZeneca



AIROMET® INHALATION AEROSOL
(Salmeterol sulfate)
100 mcg per inhalation
3M Pharmaceuticals



ATROVENT® HFA INHALATION AEROSOL
(Ipratropium bromide)
20 mcg per inhalation
Boehringer Ingelheim

RELIEVERS (Short-Acting Bronchodilators)

This is not a complete list of available agents.
Please consult the CPS for others.